CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1

CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1

Chimeric antigen comprising multimeric aggregates of the extracellular domain of the programmed death ligand 1 (PD-L1) with a reduced binding capacity to the PD-1 and CD80 receptors as compared to the native PD-L1 molecule. The invention further discloses pharmaceutical compositions including said c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: AYALA ÁVILA, Marta, GONZALEZ BLANCO, Sonia, LIMONTA FERNÁNDEZ, Miladys, ESPINOSA RODRÍGUEZ, Luis, Ariel, BESADA PÉREZ, Vladimir, Armando, MORERA DÍAZ, Yanelys, SÁNCHEZ RAMÍREZ, Javier, CANAÁN-HADEN AYALA, Camila, GONZALEZ MOYA, Isabel, BEQUET ROMERO, Mónica
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chimeric antigen comprising multimeric aggregates of the extracellular domain of the programmed death ligand 1 (PD-L1) with a reduced binding capacity to the PD-1 and CD80 receptors as compared to the native PD-L1 molecule. The invention further discloses pharmaceutical compositions including said chimeric antigen and at least a pharmaceutically acceptable vaccine adjuvant. The chimeric antigen is used for the manufacturing of a drug to treat cancer or its metastases. The invention also discloses a method of treating cancer or its metastases in a subject in need thereof, characterized by the administration of a therapeutically effective amount of the pharmaceutical composition comprising the chimeric antigen described herein.